{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:01:51Z","timestamp":1794506511829,"version":"4.9.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"41","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin\u2013angiotensin\u2013aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run-in phase with patiromer and optimization of the RAASi therapy [\u226550% recommended dose of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker\/angiotensin receptor-neprilysin inhibitor, and 50\u2005mg of mineralocorticoid receptor antagonist (MRA) spironolactone or eplerenone]. Specified target doses of the RAASi therapy were achieved in 878 (84.6%) patients; 439 were randomized to patiromer and 439 to placebo. All patients, physicians, and outcome assessors were blinded to treatment assignment. The primary endpoint was between-group difference in the adjusted mean change in serum potassium. Five hierarchical secondary endpoints were assessed. At the end of treatment, the median (interquartile range) duration of follow-up was 27 (13\u201343) weeks, the adjusted mean change in potassium was +0.03\u2005mmol\/l in the patiromer group and +0.13\u2005mmol\/l in the placebo group [difference in the adjusted mean change between patiromer and placebo: \u22120.10\u2005mmol\/l (95% confidence interval, CI \u22120.13, 0.07); P &amp;lt; 0.001]. Risk of hyperkalemia &amp;gt;5.5\u2005mmol\/l [hazard ratio (HR) 0.63; 95% CI 0.45, 0.87; P = 0.006), reduction of MRA dose (HR 0.62; 95% CI 0.45, 0.87; P = 0.006), and total adjusted hyperkalemia events\/100 person-years (77.7 vs. 118.2; HR 0.66; 95% CI 0.53, 0.81; P &amp;lt; 0.001) were lower with patiromer. Hyperkalemia-related morbidity-adjusted events (win ratio 1.53, P &amp;lt; 0.001) and total RAASi use score (win ratio 1.25, P = 0.048) favored the patiromer arm. Adverse events were similar between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Concurrent use of patiromer and high-dose MRAs reduces the risk of recurrent hyperkalemia (ClinicalTrials.gov: NCT03888066).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac401","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T11:54:45Z","timestamp":1659009285000},"page":"4362-4373","source":"Crossref","is-referenced-by-count":216,"title":["Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4267-6933","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"first","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX , USA"},{"name":"Department of Medicine, University of Mississippi , Jackson, MS , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) , Berlin , Germany"},{"name":"Berlin Institute of Health Center for Regenerative Therapies (BCRT) , Berlin , Germany"},{"name":"German Center for Cardiovascular Research (DZHK) partner site Berlin , Berlin , Germany"},{"name":"Charit\u00e9 Universit\u00e4tsmedizin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-4482","authenticated-orcid":false,"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Unit of Cardiology, Karolinska Institutet, Solna , Stockholm , Sweden"},{"name":"Department of Cardiology, Karolinska University Hospital , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J S","family":"Coats","sequence":"additional","affiliation":[{"name":"University of Warwick , Warwick , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-0332","authenticated-orcid":false,"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine, Athens University , Athens , Greece"},{"name":"Hospital Attikon , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Jamal","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX , USA"},{"name":"Department of Medicine, University of Mississippi , Jackson, MS , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-7441","authenticated-orcid":false,"given":"Tim","family":"Friede","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , G\u00f6ttingen , Germany"},{"name":"University Medical Center G\u00f6ttingen , G\u00f6ttingen , Germany"},{"name":"DZHK (German Center for Cardiovascular Research), G\u00f6ttingen partner site , G\u00f6ttingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-0756","authenticated-orcid":false,"given":"Vincent","family":"Fabien","sequence":"additional","affiliation":[{"name":"Vifor Pharma , Glattbrugg , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Saint Luke\u2019s Mid America Heart Institute , Kansas City, MO , USA"},{"name":"University of Missouri-Kansas City , Kansas City, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili and University , Brescia , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana L","family":"Pi\u00f1a","sequence":"additional","affiliation":[{"name":"Central Michigan University College of Medicine , Mount Pleasant, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Pinto","sequence":"additional","affiliation":[{"name":"Santa Maria University Hospital, CAML, CCUL, Faculdade de Medicina da Universidade de Lisboa , Lisbon , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-7932","authenticated-orcid":false,"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"X Universit\u00e9 de Lorraine, INSERM, Centre d\u2019Investigations Cliniques-Plurith\u00e9matique 1433, INSERM Unit 1116, Centre Hospitalier R\u00e9gional Universitaire (CHRU) de Nancy , Nancy , France"},{"name":"F-CRIN INI-CRCT , Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bahit","sequence":"additional","affiliation":[{"name":"INECO Neurociencias Oro\u00f1o , Rosario, Santa Fe, NM , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Belohlavek","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology and Angiology, General University Hospital Prague , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Saarland University , Homburg\/Saar , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J","family":"Brugts","sequence":"additional","affiliation":[{"name":"Erasmus MC University Medical Center , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G F","family":"Cleland","sequence":"additional","affiliation":[{"name":"Institute of Health & Wellbeing, University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Dentistry, University of Alberta , Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-197X","authenticated-orcid":false,"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari Germans Trias i Pujol , Badalona, Barcelona, CIBERCV , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Gotsman","sequence":"additional","affiliation":[{"name":"Hadassah Medical Centre , Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assen","family":"Goudev","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Sofia , Sofia , Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irakli","family":"Khintibidze","sequence":"additional","affiliation":[{"name":"Alexandre Aladashvili Clinic, Tbilisi State Medical University , Tbilisi , Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Mentz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[{"name":"Semmelweis University Heart and Vascular Center , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliodoro Castro","family":"Montes","sequence":"additional","affiliation":[{"name":"Heart Institute of Queretaro , Santiago de Quer\u00e9taro, Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost Limburg Genk and University Hasselt , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina"},{"name":"Universidade de Sao Paulo , Sao Paulo, SP , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Parkhomenko","sequence":"additional","affiliation":[{"name":"Hospital Oost-Limburg , Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Insitute of Heart Diseases, Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar M","family":"Seferovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Belgrade , Serbia"},{"name":"Serbian Academy of Sciences and Arts , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano \u2013 Bicocca, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[{"name":"Almazov Federal Heart, Blood and Endocrinology Centre , Saint-Petersburg , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1055-2231","authenticated-orcid":false,"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM U942, APHP, Hospital Lariboisiere , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szecs\u00f6dy","sequence":"additional","affiliation":[{"name":"Vifor Pharma , Glattbrugg , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Jensen","sequence":"additional","affiliation":[{"name":"Vifor Pharma , Glattbrugg , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-0242","authenticated-orcid":false,"given":"Fabio","family":"Dorigotti","sequence":"additional","affiliation":[{"name":"Vifor Pharma , Glattbrugg , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Weir","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Maryland School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"2022103123585434300_ehac401-B1","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/ejhf.1987","article-title":"Serum potassium in the PARADIGM-HF trial","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2022103123585434300_ehac401-B3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2022103123585434300_ehac401-B4","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1724","article-title":"Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"2022103123585434300_ehac401-B6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022103123585434300_ehac401-B8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"2022103123585434300_ehac401-B9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ejhf.2386","article-title":"Patiromer for the management of hyperkalaemia in patients receiving renin\u2013angiotensin\u2013aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial","volume":"24","author":"Butler","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B10","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2022103123585434300_ehac401-B11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1869","article-title":"Effects of combined renin\u2013angiotensin\u2013aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B12","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ejhf.2219","article-title":"Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum","volume":"23","author":"Bistola","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2022103123585434300_ehac401-B14","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022103123585434300_ehac401-B15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022103123585434300_ehac401-B16","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2022103123585434300_ehac401-B19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","author":"The RALES Investigators","year":"1996","journal-title":"Am J Cardiol"},{"key":"2022103123585434300_ehac401-B20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurheartj\/16.suppl_N.107","article-title":"ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES)","author":"Pitt","year":"1995","journal-title":"Eur Heart J"},{"key":"2022103123585434300_ehac401-B21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2022103123585434300_ehac401-B23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2022103123585434300_ehac401-B24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2022103123585434300_ehac401-B25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.1757","article-title":"Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry","volume":"22","author":"Cooper","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022103123585434300_ehac401-B27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ejhf.1175","article-title":"Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehac401\/45179962\/ehac401.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/41\/4362\/46683446\/ehac401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/41\/4362\/46683446\/ehac401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T19:59:52Z","timestamp":1667246392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/41\/4362\/6651164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":27,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2022,8,23]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac401","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,8,23]]}}}